A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options.
Bright Minds Announces Effective Date of Share Consolidation | Psychedelic Invest
Bright Minds Biosciences Inc. (CSE: DRUG / NASDAQ: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy,